Drug Trial News

RSS

RNAi effective in treating cancer patients

The new study published in Cancer Discovery, the flagship journal of the American Association of Cancer Research (AACR), involving three Spanish and six American research centres, presents significant results in treating cancer patients with nanoparticles containing ribonucleic acid interference (RNAi) molecules.

13 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

A stroke survivor's chances of living independently after 90 days are not improved by the use of devices inserted into the artery to dissolve or remove a stroke-causing clot shortly after the onset of symptoms, according to a randomized controlled trial involving 656 patients.

11 Feb 2013

RNL BIO files new stem cell drug IND with KFDA to initiate phase II and III cerebral palsy trials

RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III assessing the company's RNL-Astrostem stem cell drug in patients with cerebral palsy.

11 Feb 2013

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans.

10 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

New insights on role of placebo in depression

A randomized controlled trial published in one of the last issue of Psychotherapy and Psychosomatics unravels new insights on the role of placebo in depression.

10 Feb 2013

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease.

10 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013

Marijuana may double stroke risk in young adults

Marijuana, the most widely used illicit drug, may double stroke risk in young adults, according to research presented at the American Stroke Association's International Stroke Conference 2013.

9 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Drug Trial News

RNAi effective in treating cancer patients

LASAG trial for severe influenza initiated

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

RNL BIO files new stem cell drug IND with KFDA to initiate phase II and III cerebral palsy trials

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib shows promise against metastatic renal cell carcinoma

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

New insights on role of placebo in depression

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Marijuana may double stroke risk in young adults

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Academic medical centers play an integral role in developing new treatments and cures

Omega-3 fatty acids can prevent sudden cardiac death in dialysis patients

Cedars-Sinai to include more patients in hypothermia plus clot-busting drug trial for stroke

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Experimental TB vaccine does not protect infants, study shows

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News